SHILPA MEDICARE
GenericsSHILPA MEDICARE is a generic drug manufacturer focused on Oncology.
SHILPA MEDICARE's Key Drugs
SHILPA MEDICARE's core commercial portfolio centers on TENOFOVIR ALAFENAMIDE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
SHILPA MEDICARE's Recent FDA Approvals
New NDA/BLA approvals for SHILPA MEDICARE over the last two years — novel drugs only, excluding generics and label supplements.
SHILPA MEDICARE's Therapeutic Areas
SHILPA MEDICARE's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHILPA MEDICARE's Top Competitors
SHILPA MEDICARE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHILPA MEDICARE Pipeline Snapshot
Active clinical trials for SHILPA MEDICARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TENOFOVIR ALAFENAMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-09-29
- Latest
- 2024-12-23
- Applications
- 5